{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:33:17Z","timestamp":1791275597456,"version":"4.1.0"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.ijcard.2015.03.049","type":"journal-article","created":{"date-parts":[[2015,3,4]],"date-time":"2015-03-04T05:46:18Z","timestamp":1425447978000},"page":"9-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Protease-activated receptor-1 antagonists in long-term antiplatelet therapy. Current state of evidence and future perspectives"],"prefix":"10.1016","volume":"185","author":[{"given":"I.C.","family":"Moschonas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Goudevenos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.D.","family":"Tselepis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2015.03.049_bb0010","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s12265-013-9454-3","article-title":"Novel antiplatelet agents: focus on thrombin receptor antagonists","volume":"6","author":"De Souza","year":"2013","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0015","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.pharmthera.2012.01.007","article-title":"Physiology, pharmacology, and therapeutic potential of protease-activated receptors in cardiovascular disease","volume":"134","author":"Lee","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0020","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/0092-8674(91)90261-V","article-title":"Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation","volume":"64","author":"Vu","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.ijcard.2015.03.049_bb0025","doi-asserted-by":"crossref","first-page":"9208","DOI":"10.1073\/pnas.91.20.9208","article-title":"Molecular cloning of a potential proteinase activated receptor","volume":"91","author":"Nystedt","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0030","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/386502a0","article-title":"Protease-activated receptor 3 is a second thrombin receptor in humans","volume":"386","author":"Ishihara","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.ijcard.2015.03.049_bb0035","doi-asserted-by":"crossref","first-page":"6642","DOI":"10.1073\/pnas.95.12.6642","article-title":"Cloning and characterization of human protease-activated receptor 4","volume":"95","author":"Xu","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0040","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/29325","article-title":"A dual thrombin receptor system for platelet activation","volume":"394","author":"Kahn","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.ijcard.2015.03.049_bb0045","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/216857a0","article-title":"Actions of thrombin and other coagulant and proteolytic enzymes on blood platelets","volume":"216","author":"Davey","year":"1967","journal-title":"Nature"},{"key":"10.1016\/j.ijcard.2015.03.049_bb0050","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1073\/pnas.98.4.1823","article-title":"A thrombin receptor function for platelet glycoprotein Ib-IX unmasked by cleavage of glycoprotein V","volume":"98","author":"Ramakrishnan","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0055","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.1074\/jbc.M008160200","article-title":"Binding of thrombin to glycoprotein Ib accelerates the hydrolysis of Par-1 on intact platelets","volume":"276","author":"De Candia","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0060","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1042\/bj20030954","article-title":"Protease-activated receptor-4 uses dual prolines and an anionic retention motif for thrombin recognition and cleavage","volume":"376","author":"Jacques","year":"2003","journal-title":"Biochem. J."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0065","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1021\/bi9927078","article-title":"Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets","volume":"39","author":"Covic","year":"2000","journal-title":"Biochemistry"},{"key":"10.1016\/j.ijcard.2015.03.049_bb0070","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1055\/s-0037-1613071","article-title":"Role of the PAR4 thrombin receptor in stabilizing platelet\u2013platelet aggregates as revealed by a patient with Hermansky\u2013Pudlak syndrome","volume":"87","author":"Covic","year":"2002","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0075","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1161\/CIRCULATIONAHA.105.587758","article-title":"Blocking the protease-activated receptor 1\u20134 heterodimer in platelet-mediated thrombosis","volume":"113","author":"Leger","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2015.03.049_bb0080","doi-asserted-by":"crossref","first-page":"32553","DOI":"10.1074\/jbc.M113.472373","article-title":"Protease-activated receptor 1 (PAR1) and PAR4 heterodimers are required for PAR1-enhanced cleavage of PAR4 by \u03b1-thrombin","volume":"288","author":"Arachiche","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0085","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1172\/JCI116344","article-title":"The thrombin receptor extracellular domain contains sites crucial for peptide ligand-induced activation","volume":"91","author":"Bahou","year":"1993","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0090","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.chembiol.2003.10.014","article-title":"Structural basis for thrombin activation of a protease-activated receptor: inhibition of intramolecular liganding","volume":"10","author":"Seeley","year":"2003","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0095","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/368648a0","article-title":"Specificity of the thrombin receptor for agonist peptide is defined by its extracellular surface","volume":"368","author":"Gerszten","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.ijcard.2015.03.049_bb0100","doi-asserted-by":"crossref","first-page":"21619","DOI":"10.1074\/jbc.270.37.21619","article-title":"Mechanisms of thrombin receptor agonist specificity. Chimeric receptors and complementary mutations identify an agonist recognition site","volume":"270","author":"Nanevicz","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0105","doi-asserted-by":"crossref","first-page":"13943","DOI":"10.1074\/jbc.271.24.13943","article-title":"Agonist recognition by proteinase-activated receptor 2 and thrombin receptor. Importance of extracellular loop interactions for receptor function","volume":"271","author":"Lerner","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0110","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1124\/mol.58.6.1178","article-title":"Extracellular mutations of protease-activated receptor-1 result in differential activation by thrombin and thrombin receptor agonist peptide","volume":"58","author":"Blackhart","year":"2000","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0115","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1083\/jcb.144.4.745","article-title":"Activation of G12\/13 results in shape change and Rho\/Rho-kinase-mediated myosin light chain phosphorylation in mouse platelets","volume":"144","author":"Klages","year":"1999","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0120","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1096\/fj.00-0810fje","article-title":"Resistance to thromboembolism in PI3Kgamma-deficient mice","volume":"15","author":"Hirsch","year":"2001","journal-title":"FASEB J."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0125","doi-asserted-by":"crossref","first-page":"20831","DOI":"10.1016\/S0021-9258(19)36762-6","article-title":"The cloned platelet thrombin receptor couples to at least two distinct effectors to stimulate phosphoinositide hydrolysis and inhibit adenylyl cyclase","volume":"267","author":"Hung","year":"1992","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0130","doi-asserted-by":"crossref","first-page":"6081","DOI":"10.1016\/S0021-9258(18)42664-6","article-title":"Structure\u2013function relationships in the activation of platelet thrombin receptors by receptor-derived peptides","volume":"267","author":"Vassallo","year":"1992","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0135","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1042\/bj3090613","article-title":"Regulation of platelet glycoprotein IIb\/IIIa (integrin \u03b1 IIB \u03b2 3) function via the thrombin receptor","volume":"309","author":"Giesberts","year":"1995","journal-title":"Biochem. J."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0140","doi-asserted-by":"crossref","first-page":"19728","DOI":"10.1074\/jbc.M909960199","article-title":"Structure\u2013function analysis of protease-activated receptor 4 tethered ligand peptides. Determinants of specificity and utility in assays of receptor function","volume":"275","author":"Faruqi","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0145","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1124\/mol.106.033365","article-title":"PAR-1, but not PAR-4, activates human platelets through a Gi\/o\/phosphoinositide-3 kinase signaling axis","volume":"71","author":"Voss","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0150","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1182\/blood.V99.10.3629","article-title":"Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling","volume":"99","author":"Kim","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ijcard.2015.03.049_bb0155","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S0021-9258(17)42230-7","article-title":"Inhibition of thrombin receptor signaling by a G protein-coupled receptor kinase. Functional specificity among G protein-coupled receptor kinases","volume":"269","author":"Ishii","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0160","doi-asserted-by":"crossref","first-page":"7440","DOI":"10.1073\/pnas.97.13.7440","article-title":"G protein-coupled receptor kinase-5 regulates thrombin-activated signaling in endothelial cells","volume":"97","author":"Tiruppathi","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0165","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1074\/jbc.M109160200","article-title":"\u03b2-arrestins regulate protease-activated receptor-1 desensitization but not internalization or down-regulation","volume":"277","author":"Paing","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0170","doi-asserted-by":"crossref","first-page":"10020","DOI":"10.1074\/jbc.M310590200","article-title":"Termination of protease-activated receptor-1 signaling by \u03b2-arrestins is independent of receptor phosphorylation","volume":"279","author":"Chen","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0175","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ahj.2010.10.043","article-title":"Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions","volume":"161","author":"White","year":"2011","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0180","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1160\/TH08-12-0805","article-title":"The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease","volume":"102","author":"Serebruany","year":"2009","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0185","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1093\/eurheartj\/ehq320","volume":"31","author":"Goto","year":"2010","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0190","series-title":"Presented at the 2010 TCT Congress. September 21\u201325, 2010. Washington, DC","article-title":"LANCELOT ACS: a prospective, randomized, double-blind, placebo-controlled trial of a reversible PAR-1 thrombin receptor antagonist in patients with acute coronary syndromes","author":"O' Donoghue","year":"2010"},{"key":"10.1016\/j.ijcard.2015.03.049_bb0195","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0960-894X(99)00101-8","article-title":"Design, synthesis, and structure\u2013activity relationship studies of himbacine derived muscarinic receptor antagonists","volume":"9","author":"Doller","year":"1999","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0200","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1586\/ecp.12.19","article-title":"Pharmacodynamic properties of antiplatelet agents: current knowledge and future perspectives","volume":"5","author":"Kalantzi","year":"2012","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0205","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1021\/jm800180e","article-title":"Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity","volume":"51","author":"Chackalamannil","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0210","first-page":"177","article-title":"Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar","volume":"10","author":"Cho","year":"2014","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0215","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nature11701","article-title":"High-resolution crystal structure of human protease-activated receptor 1 bound to the antagonist vorapaxar","volume":"492","author":"Zhang","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ijcard.2015.03.049_bb0220","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1124\/dmd.110.035493","article-title":"Identification of human liver cytochrome P450 enzymes involved in the metabolism of SCH 530348 (vorapaxar), a potent oral thrombin protease-activated receptor 1 antagonist","volume":"39","author":"Ghosal","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0225","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1586\/erc.10.49","article-title":"Mechanism of action and clinical development of platelet thrombin receptor antagonists","volume":"8","author":"Ueno","year":"2010","journal-title":"Expert. Rev. Cardiovasc. Ther."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0230","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/jcph.20","article-title":"The effect of multiple doses of ketoconazole or rifampin on the single- and multiple-dose pharmacokinetics of vorapaxar","volume":"53","author":"Kosoglou","year":"2013","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0235","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s00228-012-1271-0","article-title":"Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin","volume":"68","author":"Kosoglou","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0240","doi-asserted-by":"crossref","first-page":"6676","DOI":"10.1016\/j.bmcl.2010.09.009","article-title":"Discovery of a vorapaxar analog with increased aqueous solubility","volume":"20","author":"Xia","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0245","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1016\/j.bmcl.2012.01.138","article-title":"Discovery of nor-seco himbacine analogs as thrombin receptor antagonists","volume":"22","author":"Chelliah","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0250","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00228-011-1120-6","article-title":"Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects","volume":"68","author":"Kosoglou","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0255","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00228-011-1127-z","article-title":"No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects","volume":"68","author":"Kosoglou","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0260","doi-asserted-by":"crossref","first-page":"889","DOI":"10.5414\/CP202121","article-title":"Pharmacokinetics of vorapaxar and its metabolite following oral administration in healthy Chinese and American subjects","volume":"52","author":"Chen","year":"2014","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0265","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1160\/TH13-07-0624","article-title":"Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER pharmacodynamic substudy","volume":"111","author":"Storey","year":"2014","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0270","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s00228-012-1217-6","article-title":"Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease","volume":"68","author":"Kosoglou","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0275","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1007\/s00228-012-1269-7","article-title":"Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment","volume":"68","author":"Statkevich","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0280","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(09)60230-0","article-title":"Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study","volume":"373","author":"Becker","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2015.03.049_bb0285","doi-asserted-by":"crossref","first-page":"156","DOI":"10.5551\/jat.3038","article-title":"Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome","volume":"17","author":"Goto","year":"2010","journal-title":"J. Atheroscler. Thromb."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0290","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1109719","article-title":"Thrombin-receptor antagonist vorapaxar in acute coronary syndromes","volume":"366","author":"Tricoci","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0295","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s11886-014-0492-5","article-title":"Universal MI definition update for cardiovascular disease","volume":"16","author":"White","year":"2014","journal-title":"Curr. Cardiol. Rep."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0300","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0305","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2015.03.049_rf0310","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"1506","key":"10.1016\/j.ijcard.2015.03.049_rf0315","first-page":"1716","volume":"345","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0315","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.ahj.2005.03.029","volume":"149","author":"Giugliano","year":"2005","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0320","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1001\/jama.297.6.591","article-title":"Routine upstream initiation vs deferred selective use of glycoprotein IIb\/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial","volume":"297","author":"Stone","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2015.03.049_bb0325","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1161\/ATVBAHA.110.203414","article-title":"SCH 602539, a protease-activated receptor-1 antagonist, inhibits thrombosis alone and in combination with cangrelor in a Folts model of arterial thrombosis in cynomolgus monkeys","volume":"30","author":"Chintala","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0330","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jstrokecerebrovasdis.2010.09.005","article-title":"Safety of the novel protease-activated receptor-1 antagonist vorapaxar in Japanese patients with a history of ischemic stroke","volume":"21","author":"Shinohara","year":"2012","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0335","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1161\/CIRCULATIONAHA.111.071589","article-title":"Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting. A randomized multicenter trial","volume":"125","author":"Valgimigli","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2015.03.049_bb0340","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1056\/NEJMoa1001266","article-title":"Duration of dual antiplatelet therapy after implantation of drug-eluting stents","volume":"362","author":"Park","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0345","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0350","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","article-title":"Vorapaxar in the secondary prevention of atherothrombotic events","volume":"366","author":"Morrow","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0355","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ahj.2009.06.027","volume":"158","author":"Morrow","year":"2009","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0360","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1161\/STROKEAHA.111.000433","article-title":"Efficacy and safety of vorapaxar in patients with prior ischemic stroke","volume":"44","author":"Morrow","year":"2013","journal-title":"Stroke"},{"key":"10.1016\/j.ijcard.2015.03.049_bb0365","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1093\/eurheartj\/eht104","article-title":"Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA-CER) trial","volume":"34","author":"Leonardi","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0370","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S0140-6736(12)61269-0","article-title":"Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2P-TIMI 50 trial","volume":"380","author":"Scirica","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2015.03.049_bb0375","first-page":"A10398","article-title":"Vorapaxar in patients with diabetes and prior MI: findings from the TRA 2P-TIMI 50 trial","volume":"128","author":"Scirica","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2015.03.049_bb0380","doi-asserted-by":"crossref","first-page":"A18805","DOI":"10.1161\/circ.126.suppl_21.A18805","article-title":"Vorapaxar, a platelet thrombin-receptor antagonist, in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: results from the TRACER trial","volume":"126","author":"Valgimigli","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2015.03.049_bb0385","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.amjcard.2014.05.054","article-title":"Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER trial)","volume":"114","author":"Valgimigli","year":"2014","journal-title":"Am. J. Cardiol."},{"issue":"Suppl. 1","key":"10.1016\/j.ijcard.2015.03.049_bb0390","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/eurheartj\/eht307.P240","article-title":"Lack of concordance between angiographic core laboratory and CEC in the assessment of stent thrombosis: results from the TRACER angiographic substudy","volume":"34","author":"Gibson","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0395","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1016\/j.jacc.2014.09.037","article-title":"Coronary stent thrombosis with vorapaxar versus placebo. Results from the TRA 2P-TIMI 50 trial","volume":"64","author":"Bonaca","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0400","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1161\/CIRCULATIONAHA.112.000679","article-title":"Vorapaxar in patients with peripheral artery disease: results from TRA 2P-TIMI 50","volume":"127","author":"Bonaca","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2015.03.049_bb0405","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.jacc.2013.10.048","article-title":"Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery. Subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome)","volume":"63","author":"Whellan","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0410","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1016\/j.jacc.2014.07.997","article-title":"New ischemic stroke and outcomes with vorapaxar versus placebo. Results from the TRA 2P-TIMI 50 trial","volume":"64","author":"Bonaca","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0415","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.amjcard.2013.11.052","article-title":"Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER trial)","volume":"113","author":"Mahaffey","year":"2014","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2015.03.049_bb0420","first-page":"A14508","article-title":"Vorapaxar for secondary prevention after myocardial infarction according to aspirin dose-insights from the TRA 2P-TIMI 50 trial","volume":"126","author":"Scirica","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2015.03.049_bb0425","first-page":"495","article-title":"Vorapaxar with and without thienopyridine use in acute coronary syndromes: results from the TRACER trial","volume":"33","author":"Tricoci","year":"2012","journal-title":"Eur. Heart J."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527315002879?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527315002879?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T16:11:54Z","timestamp":1717776714000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527315002879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":85,"alternative-id":["S0167527315002879"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2015.03.049","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Protease-activated receptor-1 antagonists in long-term antiplatelet therapy. Current state of evidence and future perspectives","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2015.03.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}